United Therapeutics Corporation (NASDAQ:UTHR)‘s stock had its “buy” rating reiterated by stock analysts at Oppenheimer Holdings, Inc. in a research note issued to investors on Tuesday.

A number of other brokerages have also recently issued reports on UTHR. Cowen and Company set a $144.00 price target on shares of United Therapeutics Corporation and gave the company a “buy” rating in a research report on Thursday, October 27th. Wedbush reissued an “outperform” rating and set a $229.00 price target on shares of United Therapeutics Corporation in a research report on Thursday, January 5th. Zacks Investment Research raised shares of United Therapeutics Corporation from a “hold” rating to a “buy” rating and set a $161.00 price target for the company in a research report on Friday, January 6th. Ladenburg Thalmann Financial Services raised shares of United Therapeutics Corporation from a “neutral” rating to a “buy” rating and lifted their price target for the company from $128.00 to $138.00 in a research report on Friday, October 28th. Finally, Barclays PLC cut shares of United Therapeutics Corporation from an “equal weight” rating to an “underweight” rating and lowered their price target for the company from $115.00 to $100.00 in a research report on Tuesday, November 29th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and four have issued a buy rating to the stock. United Therapeutics Corporation has an average rating of “Hold” and an average target price of $136.42.

Analyst Recommendations for United Therapeutics Corporation (NASDAQ:UTHR)

United Therapeutics Corporation (NASDAQ:UTHR) opened at 168.42 on Tuesday. The firm has a 50-day moving average of $156.15 and a 200-day moving average of $133.21. United Therapeutics Corporation has a 1-year low of $97.52 and a 1-year high of $168.82. The stock has a market capitalization of $7.14 billion, a PE ratio of 11.40 and a beta of 1.42.

“United Therapeutics Corporation (UTHR) Rating Reiterated by Oppenheimer Holdings, Inc.” was first posted by Daily Political and is the sole property of of Daily Political. If you are viewing this article on another publication, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The legal version of this article can be viewed at http://www.dailypolitical.com/2017/02/17/united-therapeutics-corporation-uthr-rating-reiterated-by-oppenheimer-holdings-inc.html.

In other United Therapeutics Corporation news, Director Richard Giltner sold 5,000 shares of the firm’s stock in a transaction dated Tuesday, December 6th. The shares were sold at an average price of $133.37, for a total transaction of $666,850.00. Following the completion of the sale, the director now directly owns 5,000 shares in the company, valued at approximately $666,850. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Martine A. Rothblatt sold 1,246 shares of the firm’s stock in a transaction dated Thursday, December 1st. The shares were sold at an average price of $126.86, for a total transaction of $158,067.56. Following the sale, the chief executive officer now owns 1,386 shares of the company’s stock, valued at $175,827.96. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 19,778 shares of company stock valued at $2,728,567. 7.50% of the stock is owned by company insiders.

Hedge funds have recently made changes to their positions in the company. Ladenburg Thalmann Financial Services Inc. raised its stake in shares of United Therapeutics Corporation by 11.3% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 717 shares of the biotechnology company’s stock worth $104,000 after buying an additional 73 shares in the last quarter. Focused Wealth Management Inc bought a new stake in shares of United Therapeutics Corporation during the fourth quarter worth approximately $115,000. Nordea Investment Management AB raised its stake in shares of United Therapeutics Corporation by 18.7% in the second quarter. Nordea Investment Management AB now owns 1,208 shares of the biotechnology company’s stock worth $128,000 after buying an additional 190 shares in the last quarter. Daiwa Securities Group Inc. raised its stake in shares of United Therapeutics Corporation by 9.5% in the third quarter. Daiwa Securities Group Inc. now owns 1,150 shares of the biotechnology company’s stock worth $136,000 after buying an additional 100 shares in the last quarter. Finally, BancorpSouth Inc bought a new stake in shares of United Therapeutics Corporation during the third quarter worth approximately $224,000.

About United Therapeutics Corporation

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. Its therapeutic products and product candidates include Prostacyclin Analogues, Phosphodiesterase Type 5 (PDE-5) Inhibitor and Monoclonal Antibody (MAb).

5 Day Chart for NASDAQ:UTHR

Receive News & Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.